Company & Sponsor Intelligence

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials14

Recruiting0

Completed14

Countries2

Therapeutic footprint

adhdalzheimersautismepilepsyschizophrenia

Indexed studies

NCT00253188A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's Disease
alzheimers · PHASE3

NCT01812642A Pharmacokinetics Study to Evaluate Safety and Tolerability of JNJ-37822681 in Participants With Stable Schizophrenia
schizophrenia · BelgiumPHASE2

NCT00236756A Study of the Efficacy and Safety of Topiramate as an add-on Therapy in the Treatment of Epilepsy Patients With Lennox-Gastaut Syndrome
epilepsy · PHASE3

NCT00880217A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
adhd · United StatesPHASE2

NCT00576732A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder
autism · United StatesPHASE4

NCT00082602Safety and Tolerability Study of Extended Release (ER) Galantamine in Alzheimer's Disease
alzheimers · PHASE3

NCT00236860A Study of the Efficacy and Safety of Topiramate as add-on Therapy in the Treatment of Epilepsy Patients With Difficult to Treat, Partial-onset Seizures
epilepsy · PHASE2

NCT00266604A Study to Evaluate the Dosing, Effectiveness and Safety of Topiramate for the Treatment of Epilepsy
epilepsy · PHASE4

NCT00236743A Study of the Effectiveness and Safety of Topiramate in the Treatment of Children With Epilepsy
epilepsy · PHASE3

NCT00236444A Study of the Efficacy and Safety of Risperidone in the Prevention of Relapse in Children and Adolescents With Conduct and Other Disruptive Behavior Disorders
adhd · PHASE3

NCT00236847A Study of the Efficacy and Safety of Topiramate in the Treatment of Patients With Epilepsy.
epilepsy · PHASE2

NCT00034762Efficacy and Safety of Risperidone Compared With Placebo in the Treatment of Psychotic Symptoms in Patients With Alzheimer's Disease
alzheimers · PHASE3

Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →